Research summary ·
Very late-onset myasthenia gravis: a systematic review and meta-analysis of sex distribution, thymic pathology and autoantibodies.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review compared very late-onset myasthenia gravis with earlier-onset forms. Very late onset means age 65 years or older. The team also used the usual early and late onset groups, split at 50 years. It searched MEDLINE, Embase, CENTRAL and Google Scholar through May 2026. It pooled odds ratios for sex, antibodies, thymoma and thymic hyperplasia.
What they found
Against onset before age 65, very late onset had more AChR antibodies, at 3.08. It had less double-seronegativity, at 0.34. It had less thymoma, at 0.25. MuSK antibodies were lower, at 0.50, but this did not meet the adjusted threshold. Female share did not differ significantly. Late onset against early onset had fewer women, at 0.32. It also had less thymic hyperplasia, at 0.45. Titin antibodies were higher in late onset, at 10.00, in an exploratory test.
What it means for patients
The team says later onset goes with more AChR-positive disease. It also goes with less MuSK positivity, seronegativity and thymic disease. They say the findings support splitting onset into early, intermediate and very late groups.
Why it is not certain yet
Several results did not meet the adjusted significance threshold. The titin result was exploratory. The abstract does not say how many people were included. A review can only be as good as the studies in it.
Source
Very late-onset myasthenia gravis: a systematic review and meta-analysis of sex distribution, thymic pathology and autoantibodies.
PubMed · PMID 42461294We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Thymoma and thymic carcinoma publications